Nabriva Therapeutics plc - Ordinary Shares (NBRV): Price and Financial Metrics


Nabriva Therapeutics plc - Ordinary Shares (NBRV): $0.19

-0.01 (-6.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NBRV POWR Grades


  • Growth is the dimension where NBRV ranks best; there it ranks ahead of 92.22% of US stocks.
  • The strongest trend for NBRV is in Value, which has been heading up over the past 145 days.
  • NBRV ranks lowest in Stability; there it ranks in the 2nd percentile.

NBRV Stock Summary

  • NBRV's price/sales ratio is 12.14; that's higher than the P/S ratio of 87.95% of US stocks.
  • Revenue growth over the past 12 months for Nabriva Therapeutics plc comes in at 661.86%, a number that bests 98.51% of the US stocks we're tracking.
  • In terms of volatility of its share price, NBRV is more volatile than 91.26% of stocks we're observing.
  • Stocks that are quantitatively similar to NBRV, based on their financial statements, market capitalization, and price volatility, are DTSS, TRVG, CSPI, SSD, and AGRX.
  • Visit NBRV's SEC page to see the company's official filings. To visit the company's web site, go to www.nabriva.com.

NBRV Valuation Summary

  • NBRV's price/sales ratio is 36.3; this is 219.82% higher than that of the median Healthcare stock.
  • Over the past 65 months, NBRV's EV/EBIT ratio has gone down 0.
  • NBRV's price/earnings ratio has moved down 3.4 over the prior 65 months.

Below are key valuation metrics over time for NBRV.

Stock Date P/S P/B P/E EV/EBIT
NBRV 2021-08-31 36.3 7.6 -9.3 -8.6
NBRV 2021-08-30 36.6 7.7 -9.4 -8.7
NBRV 2021-08-27 36.3 7.6 -9.3 -8.6
NBRV 2021-08-26 35.3 7.4 -9.1 -8.4
NBRV 2021-08-25 36.0 7.5 -9.2 -8.5
NBRV 2021-08-24 36.3 7.6 -9.3 -8.6

NBRV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NBRV has a Quality Grade of D, ranking ahead of 14.14% of graded US stocks.
  • NBRV's asset turnover comes in at 0.2 -- ranking 199th of 681 Pharmaceutical Products stocks.
  • TECH, PRTA, and RYTM are the stocks whose asset turnover ratios are most correlated with NBRV.

The table below shows NBRV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.200 0.720 -4.035
2021-03-31 0.104 0.879 -5.458
2020-12-31 0.091 0.848 -7.042
2020-09-30 0.045 0.843 -4.960
2020-06-30 0.118 0.948 -3.969
2020-03-31 0.111 0.991 -3.268

NBRV Price Target

For more insight on analysts targets of NBRV, see our NBRV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.68 Average Broker Recommendation 1.83 (Hold)

NBRV Stock Price Chart Interactive Chart >

Price chart for NBRV

NBRV Price/Volume Stats

Current price $0.19 52-week high $1.41
Prev. close $0.20 52-week low $0.18
Day low $0.19 Volume 234,100
Day high $0.20 Avg. volume 484,963
50-day MA $0.24 Dividend yield N/A
200-day MA $0.61 Market Cap 120.72M

Nabriva Therapeutics plc - Ordinary Shares (NBRV) Company Bio


Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company was founded in 2006 and is based in Wien, Austria.


NBRV Latest News Stream


Event/Time News Detail
Loading, please wait...

NBRV Latest Social Stream


Loading social stream, please wait...

View Full NBRV Social Stream

Latest NBRV News From Around the Web

Below are the latest news stories about Nabriva Therapeutics plc that investors may wish to consider to help them evaluate NBRV as an investment opportunity.

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022

— Meeting to Reconvene on March 24, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders (EGM) on January 18, 2022 to allow the Company to solicit from its shareholders

Yahoo | January 18, 2022

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders

— Meeting to Reconvene on January 18, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders (EGM) on January 14, 2022 to allow the Company to solicit from its shareholder

Yahoo | January 14, 2022

H.C. Wainwright Keeps a Hold Rating on Nabriva (NBRV)

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Nabriva (NBRV – Research Report). The company's shares closed last Monday at $0.59, close to its 52-week low of $0.56. According to TipRanks.com, Arce is a 4-star analyst with an average return of 14.1% and a 38.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Nabriva. See the top stocks recommended by analysts >> The company has a one-year high of $3.49 and a one-year low of $0.56.

Howard Kim on TipRanks | January 11, 2022

Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021

-SIVEXTRO® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022- -XENLETA® (lefamulin) Phase I Cystic Fibrosis (CF) trial on track to enroll first patient in Q122- -Cash resources of $47.7 million as of 12/31/21 provides cash runway well into Q422- DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infe

Yahoo | January 10, 2022

Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021

Meeting to Reconvene on January 14, 2022 Meeting to Reconvene on January 14, 2022

Intrado Digital Media | December 22, 2021

Read More 'NBRV' Stories Here

NBRV Price Returns

1-mo N/A
3-mo -54.76%
6-mo -68.28%
1-year -86.03%
3-year -99.22%
5-year -99.82%
YTD -68.28%
2021 -75.25%
2020 -81.67%
2019 -9.59%
2018 -75.59%
2017 0.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5558 seconds.